Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

3.28
-0.0100-0.30%
Post-market: 3.280.00000.00%19:30 EDT
Volume:2.89M
Turnover:9.61M
Market Cap:714.07M
PE:-7.21
High:3.42
Open:3.31
Low:3.27
Close:3.29
52wk High:8.21
52wk Low:1.90
Shares:217.70M
Float Shares:180.00M
Volume Ratio:1.08
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4548
EPS(LYR):-0.1500
ROE:-37.75%
ROA:-19.58%
PB:2.36
PE(LYR):-21.87

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics

Reuters
·
Jun 03

BUZZ-CytomX rises on expanded Regeneron deal with up to $4 billion in milestones

Reuters
·
Jun 03

CytomX expands Regeneron bispecific cancer therapy collaboration, receives $37 million payment

Reuters
·
Jun 03

CytomX Announces Expansion of Strategic Research Collaboration With Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

THOMSON REUTERS
·
Jun 03

CytomX Therapeutics - Regeneron Secures Option for 6 Additional Targets; Total Milestones up to About $4 Bln

THOMSON REUTERS
·
Jun 03

CytomX Therapeutics - to Receive $37 Mln Target Selection Payment for Two Additional Programs

THOMSON REUTERS
·
Jun 03

CytomX Therapeutics - Eligible for Tiered Global Net Sales Royalties Under Collaboration

THOMSON REUTERS
·
Jun 03

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

TIPRANKS
·
May 23

CytomX Therapeutics publishes 2025 annual report

Reuters
·
May 22

CytomX Therapeutics to Present at Upcoming June Investor Conferences

GlobeNewswire
·
May 21

Wolfe Research Initiates CytomX Therapeutics With Outperform Rating

MT Newswires Live
·
May 19

CytomX Therapeutics initiated with an Outperform at Wolfe Research

TIPRANKS
·
May 19

CytomX names Mamata Gokhale as senior vice president of regulatory affairs

Reuters
·
May 18

CytomX Therapeutics Appoints Mamata Gokhale, Ph.d., Rac, as Senior Vice President of Regulatory Affairs

THOMSON REUTERS
·
May 18

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

GlobeNewswire
·
May 18

CytomX’s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar

TIPRANKS
·
May 16

CytomX Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

CytomX Therapeutics: Early-Stage Pipeline, Trial Setbacks and High Risks on the Road to Profitability

TIPRANKS
·
May 09

Oppenheimer Keeps Their Buy Rating on CytomX Therapeutics (CTMX)

TIPRANKS
·
May 08

CytomX Therapeutics (CTMX) Gets a Buy from Barclays

TIPRANKS
·
May 08